Page 9 - Valuating News Today

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable

First Abu Dhabi Bank , the United Arab Emirates biggest lender, said on Friday it was not currently evaluating an offer for Britains Standard Chartered. News of the potential offer... | February 10, 2023

Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms Data

Indias Adani Total Gas reported a 17.2% rise in quarterly profit on Thursday on price hikes and short-term contracts, and the company said it was evaluating an independent review following a U.S.... | February 9, 2023

WASHINGTON (dpa-AFX) - Biotechnology company INOVIO Pharmaceuticals, Inc. (INO) announced Thursday positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate,

Results presented today at ASCO GI include first overall survival (OS) data for zanidatamab, overall confirmed objective response rate (cORR) of 79%, disease control rate (DCR) of

Trial also met primary endpoint in first study population as announced September 2022 - The Company plans to work with the FDA to design a Phase 3 program to begin in 2023, ahead of expectations - Horizon

As war rages in Ukraine and inflation impacts the economy, financial institutions in the UK expect the subsequent economic downturn to drive a rise in financial crime. LONDON, Jan. 18,

Relief Therapeutics Holding SA / Key word(s): Study Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom

The Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study Oakville, Ontario--(Newsfile Corp. - January 17, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol"